44,040 Shares in Vericel Corporation (NASDAQ:VCEL) Bought by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Vericel Corporation worth approximately $1,965,000, representing about 0.09% ownership at the end of Q1.
• Analysts have mixed views on Vericel, with a consensus rating of "Moderate Buy" and a target price averaging $61.14, despite Truist Financial reducing its target from $61.00 to $51.00.
• Vericel reported a quarterly revenue of $52.60 million but missed earnings estimates, with an EPS of ($0.23) compared to the anticipated ($0.09).

Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in Vericel Corporation (NASDAQ:VCEL - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 44,040 shares of the biotechnology company's stock, valued at approximately $1,965,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.09% of Vericel as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Vericel in the fourth quarter valued at approximately $57,000. Meeder Asset Management Inc. grew its position in shares of Vericel by 8.4% in the fourth quarter. Meeder Asset Management Inc. now owns 2,357 shares of the biotechnology company's stock valued at $129,000 after purchasing an additional 183 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Vericel by 34.8% in the first quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock valued at $129,000 after purchasing an additional 748 shares during the last quarter. Mackenzie Financial Corp acquired a new position in shares of Vericel in the fourth quarter valued at approximately $215,000. Finally, Syon Capital LLC acquired a new position in shares of Vericel in the fourth quarter valued at approximately $257,000.

Vericel Stock Up 2.0%

Shares of VCEL stock traded up $0.69 during trading hours on Friday, reaching $35.63. The company's stock had a trading volume of 962,793 shares, compared to its average volume of 498,354. The firm's 50 day simple moving average is $40.93 and its 200-day simple moving average is $45.72. The company has a market capitalization of $1.79 billion, a price-to-earnings ratio of 1,188.06 and a beta of 1.32. Vericel Corporation has a fifty-two week low of $33.09 and a fifty-two week high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. Vericel had a return on equity of 1.09% and a net margin of 1.25%. The company had revenue of $63.24 million for the quarter, compared to the consensus estimate of $64.61 million. During the same quarter last year, the business posted ($0.10) EPS. Vericel's revenue for the quarter was up 20.1% on a year-over-year basis. Sell-side analysts predict that Vericel Corporation will post 0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on VCEL. Wall Street Zen downgraded Vericel from a "hold" rating to a "sell" rating in a research report on Monday, May 12th. Canaccord Genuity Group reduced their price target on Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a research report on Friday. Truist Financial reduced their price target on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research report on Friday, April 11th. Finally, Stephens reissued an "overweight" rating and set a $67.00 price target on shares of Vericel in a research report on Monday, June 16th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $59.86.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.